Cabometyx is a cancer medicine used to treat adults with: - advanced renal cell carcinoma (a kidney cancer). It is used in patients who have been previously treated with a type of cancer medicine called ‘vascular endothelial growth factor (VEGF) inhibitor’. It is also used in patients who have not had previous treatment and whose cancer is at moderate or high risk of rapidly getting worse. - hepatocellular carcinoma (a liver cancer). It is used on its own in patients who have already been treated with the cancer medicine sorafenib. - differentiated thyroid carcinoma (a type of cancer originating from the follicular cells of the thyroid gland). Cabometyx is used after systemic therapy (affecting the whole body) when the cancer has progressed or spread locally or to other parts of the body. It is used when the cancer does not respond to treatment with radioactive iodine or in patients who cannot have radioactive iodine. Cabometyx contains the active substance cabozantinib.
Therapeutic Indication
### Therapeutic indication **Renal Cell Carcinoma (RCC)** Cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (RCC): - in treatment-naïve adults with intermediate or poor risk, - in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. Cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. **Hepatocellular Carcinoma (HCC)** Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.
Therapeutic Area (MeSH)
N/AATC Code
L01EX07
ATC Item
cabozantinib
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| cabozantinib (s)-malate | N/A | Cabozantinib (s)-Malate |
EMA Name
Cabometyx
Medicine Name
Cabometyx
Aliases
N/ANo risk management plan link.
